Search Results

You are looking at 81 - 90 of 171 items for :

  • "Cervical cancer" x
Clear All
Full access

the NCCN Guidelines Panel for Uterine/Cervical Cancers in 1997, helping clinicians stay up-to-date on evidence-based treatment standards; he was named panel Co-Chair in 2004. His work is an integral part of the ongoing creation of the NCCN Harmonized

Full access

order of incidence: non-Hodgkin's lymphoma, Kaposi sarcoma, lung cancer, anal cancer, prostate cancer, liver cancer, colorectal cancer, Hodgkin lymphoma, oral/pharyngeal cancer, female breast cancer, and cervical cancer. The new NCCN Guidelines for

Full access

Ellen L. Jones, Lawrence B. Marks and Leonard R. Prosnitz

therapy versus thermoradiotherapy in stage IIIB cervical carcinoma . Int J Hyperthermia 2001 ; 27 : 97 – 105 . 18. van der Zee J Gonzalez GD . The Dutch Deep Hyperthermia Trial: results in cervical cancer . Int J Hyperthermia 2002 ; 18

Full access

Benjamin O. Anderson

VD Jeronimo J Anderson BO . Why the time is right to tackle breast and cervical cancer in low-resource settings . Bull World Health Organ 2013 ; 91 : 683 – 690 . 7. Anderson BO Carlson RW . Guidelines for improving breast health care

Full access

2019 17 17 8 8 957 957 967 967 jnccn18278 10.6004/jnccn.2019.7286 Benefit of Cisplatin With Definitive Radiotherapy in Older Women With Cervical Cancer Xiang Michael MD, PhD Kidd Elizabeth A. MD 08 2019 17 17 8 8 969 969 975 975 jnccn18514 10.6004/jnccn

Full access

.0026 NCCN Guidelines® Insights NCCN Guidelines Insights: Cervical Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines Abu-Rustum Nadeem R. 1 MD Yashar Catheryn M. 2 MD Bean Sarah 3 MD Bradley Kristin 4 MD Campos Susana M. 5 MD, MPH, MS Chon Hye

Full access

Pranammya Dey, Angela K. Green, Michael Haddadin, Peter B. Bach and Aaron P. Mitchell

Guidelines Panels were counted more than once. We defined “female-predominant cancers” as including breast, ovarian, uterine, and cervical cancers. Results In 2013, there were 123 women among 541 total panelists (22.7%); in 2019, there were 175 women out of

Full access

Ernest S. Han and Mark Wakabayashi

on uterine and cervical cancers. Most studies involve nonrandomized retrospective reviews of institutional experiences. A recent phase III trial comparing laparoscopy to laparotomy for uterine cancer staging in 1682 patients reported that the

Full access

Joseph M. Pepek, Christopher G. Willett and Brian G. Czito

% in patients treated with IMRT-based chemoradiation, other investigators have suggested improved bone marrow sparing with this approach. Brixey et al. 37 found lower rates of acute hematologic toxicity among patients with cervical cancer treated

Full access

Carolina Villanueva, Jenny Chang, Scott M. Bartell, Argyrios Ziogas, Robert Bristow and Verónica M. Vieira

patients’ travel distance found that those residing farthest from the hospital had worse cervical cancer outcomes, 45 yet a similar analysis of patients with gynecologic malignancies treated at an NCI-designated center found that those living <10 miles